Who Exports Glibenclamide from India — 194 Suppliers Behind a $41.2M Market
India's glibenclamide export market is supplied by 194 active exporters who collectively shipped $41.2M across 930 shipments. MEDOPHARM leads with a 1.0% market share, followed by M. J. BIOPHARM PRIVATE LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED. The top 5 suppliers together control 3.6% of total export value, reflecting a moderately competitive market structure.
Top Glibenclamide Exporters from India — Ranked by Export Value
MEDOPHARM is the leading glibenclamide exporter from India, holding a 1.0% share of the $41.2M market across 930 shipments from 194 exporters. The top 5 suppliers — MEDOPHARM, M. J. BIOPHARM PRIVATE LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, CIPLA LIMITED, CAPLIN POINT LABORATORIES LIMITED — collectively control 3.6% of total export value, indicating a competitive market. Individual shares are: MEDOPHARM (1.0%), M. J. BIOPHARM PRIVATE LIMITED (0.9%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (0.7%), CIPLA LIMITED (0.6%), CAPLIN POINT LABORATORIES LIMITED (0.4%).
Top Glibenclamide Exporters from India
Ranked by export value · 194 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MEDOPHARM GLIBENCLAMIDE 5MG/CLOTRIMAZOLE 1 20GGLIBENCLAMIDE TABLETS BP 5MGGLIBENCLAMIDE TABLETS BP 5 MG | $420.3K | 12 | 1.0% |
| 2 | M. J. BIOPHARM PRIVATE LIMITED GLUCONORM TABLETS (GLIBENCLAMIDE 2.5 MGGLUCONORM TABLETS 118600 PACKS OF 20 TABSGLUCONORM TABLETS [GLIBENCLAMIDE 2.5 MG | $375.5K | 2 | 0.9% |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED GLUCORED FORTE TABLETS(GLIBENCLAMIDE 5MGGLUCORED FORTE TABLETS GLIBENCLAMIDE 5MGLUCORED FORTE TABLETS (GLIBENCLAMIDE 5M | $274.9K | 1 | 0.7% |
| 4 | CIPLA LIMITED GLINIL 5MG TABLET [540X10X10'S]GLINIL 5MG TABLET [1GLINIL 5MG TABLET [4 | $235.1K | 1 | 0.6% |
| 5 | CAPLIN POINT LABORATORIES LIMITED | $169.2K | 5 | 0.4% |
| 6 | LINCOLN PHARMACEUTICALS LTD GLUCORED FORTE TABLETS(GLIBENCLAMIDE 5MGGLUCORED FORTE TABLETS GLIBENCLAMIDE 5MGLUCORED FORTE TABLETS (GLIBENCLAMIDE 5M | $124.9K | 5 | 0.3% |
| 7 | ZYDUS LIFESCIENCES LIMITED GLUCORED FORTE TABLETS(GLIBENCLAMIDE 5MGGLUCORED FORTE TABLETS GLIBENCLAMIDE 5MGLUCORED FORTE TABLETS (GLIBENCLAMIDE 5M | $116.0K | 5 | 0.3% |
| 8 | MEDICAMEN BIOTECH LIMITED GLIBENCLAMIDE TABLETS BP 5 MG 10X10,GLIBENCLAMIDE TABLET BP 5 MG 10X10 | $110.9K | 8 | 0.3% |
| 9 | RUSAN PHARMA LIMITED GLIBENCLAMIDE 5 OETHMAAN TABLETS PRP56GLIBENCLAMIDE 5 OETHMAANTABLETS PRP56GLIBENWISE 5 (GLIBENCLAMIDE TABLETS BP 5 | $107.8K | 1 | 0.3% |
| 10 | S KANT HEALTHCARE LIMITED GLIBENCLAMIDE 5MG/CLOTRIMAZOLE 1 20GGLINIL 5MG TABLET [540X10X10'S]GLIBENCLAMIDE 5 OETHMAAN TABLETS PRP56 | $104.7K | 4 | 0.3% |
| 11 | INTERMED LABORATORIES PRIVATE LIMITED | $92.2K | 2 | 0.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Glibenclamide exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Medopharm Private Limited | Not Listed | Yes, January 2025 | No | Not verified | WHO-GMP certified in January 2025. |
| S Kant Healthcare Limited | Not Listed | Yes, February 2025 | No | Not verified | WHO-GMP certified in February 2025. |
| Sun Pharmaceutical Industries Limited | Approved | Yes | Yes | Multiple | FDA-approved with multiple ANDAs; holds WHO-GMP and EU GMP certifications. |
| Cipla Limited | Approved | Yes | Yes | Multiple | FDA-approved with multiple ANDAs; holds WHO-GMP and EU GMP certifications. |
| Zydus Lifesciences Limited | Approved | Yes | Yes | Multiple | FDA-approved with multiple ANDAs; holds WHO-GMP and EU GMP certifications; recei |
| Intas Pharmaceuticals Limited | Approved | Yes | Yes | Multiple | FDA-approved with multiple ANDAs; holds WHO-GMP and EU GMP certifications. |
TransData Nexus reviewed the regulatory standing of 6 leading Glibenclamide exporters from India. 4 hold US FDA facility approvals, 6 maintain WHO-GMP certification, and 4 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Glibenclamide sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a central hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts Genome Valley, India's first biotech cluster, and is home to over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories, Aurobindo Pharma, and Divi’s Laboratories. This concentration of industry and advanced R&D infrastructure makes Hyderabad a key player in the pharmaceutical sector.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and houses a mature pharma ecosystem. The region is home to companies such as Zydus Cadila, Intas Pharmaceuticals, Torrent Pharmaceuticals, and Cadila Pharmaceuticals. The strong support infrastructure, including ports, roads, and utilities, further enhances its appeal as a formulations hub.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for pharmaceuticals. With 929 pharmaceutical units, Maharashtra is a significant contributor to India's pharma industry. The region's proximity to major ports facilitates efficient export operations, making it a strategic location for companies aiming to access international markets.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, part of the Baddi-Barotiwala-Nalagarh (BBN) industrial area in Himachal Pradesh, has emerged as a prominent pharmaceutical manufacturing hub. The region offers tax incentives and a favorable business environment, attracting numerous pharmaceutical companies. Baddi is recognized as the largest pharmaceutical hub in Asia, contributing significantly to India's healthcare manufacturing sector.
5Sourcing Recommendations
- Diversify Supplier Base: Given the low concentration among top exporters (3.6%), it's advisable to engage with multiple suppliers to mitigate risks associated with over-reliance on a single source.
- Leverage Regional Specializations: Utilize Hyderabad for API sourcing, Ahmedabad-Vadodara for formulations, and Mumbai-Thane-Raigad for export logistics to optimize the supply chain.
- Evaluate Supplier Credentials: Prioritize suppliers with WHO GMP or EU GMP certifications to ensure compliance with international quality standards.
- Monitor Export Destinations: With Sri Lanka accounting for 89.8% of Glibenclamide exports, consider market diversification strategies to reduce dependency on a single market.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Glibenclamide exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma acquires remaining stake in Taro Pharmaceuticals
Sun Pharma entered into a definitive merger agreement to acquire the remaining stake in Taro Pharmaceuticals for $347.73 million. This acquisition consolidates Sun Pharma's dermatology portfolio and enhances its presence in the U.S. market. - IMPACT: This consolidation may streamline operations, potentially affecting Glibenclamide production and export strategies.
Impact: This consolidation may streamline operations, potentially affecting Glibenclamide production and export strategies.
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for $355 million
Sun Pharma announced the acquisition of Checkpoint Therapeutics, an immunotherapy and targeted oncology company, for $355 million. This move aims to strengthen Sun Pharma's oncology pipeline and expand its specialty product offerings. - IMPACT: While primarily focused on oncology, the acquisition could lead to resource reallocation, indirectly influencing Glibenclamide export volumes.
Impact: While primarily focused on oncology, the acquisition could lead to resource reallocation, indirectly influencing Glibenclamide export volumes.
Cipla Limited — Cipla acquires Ivia Beaute’s personal care brands
Cipla acquired the distribution and marketing business of Ivia Beaute Pvt Ltd for ₹130 crore, with an additional ₹110 crore as milestone-based consideration. This acquisition is part of Cipla’s strategy to expand its consumer health vertical. - IMPACT: The focus on consumer health may divert attention from pharmaceutical exports, potentially impacting Glibenclamide export priorities.
Impact: The focus on consumer health may divert attention from pharmaceutical exports, potentially impacting Glibenclamide export priorities.
Common Questions — Glibenclamide Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which glibenclamide supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MEDOPHARM leads with 48 recorded shipments worth $420.3K. M. J. BIOPHARM PRIVATE LIMITED (10 shipments) and SUN PHARMACEUTICAL INDUSTRIES LIMITED (9 shipments) are also established high-volume exporters.
Q How many glibenclamide manufacturers are there in India?
India has 194 active glibenclamide exporters with a combined export market of $41.2M across 930 shipments to 100 countries. The top 5 suppliers hold 3.6% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for glibenclamide from India?
Average FOB unit price: $1.47 per unit, ranging from $0.00 to $51.06. Average shipment value: $44.3K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 194 verified Indian exporters of Glibenclamide ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 930 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 100 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
930 Verified Shipments
194 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists